MTOR and breast carcinoma: For high-risk BCCs based on histopathological subtypes with aggressive features, up-regulated genes of interest included CDKN2A, whose germline mutations are implicated in hereditary malignant melanoma (30), BCAT1, an amino acid transaminase implicated in breast cancer progression through increased mTOR-mediated mitochondrial activity (31), and AIM2, a contributor to tumoral inflammation in cutaneous squamous cell carcinoma (32).